Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 3,702	$ 3,230
General and administrative	4,971	3,826
Intangible asset impairment charge	0	5,900
Fair value adjustment for contingent consideration	2,545	0
Total operating expenses	11,218	12,956
Loss from operations	(11,218)	(12,956)
Fair value adjustment for long-term debt	(388)	0
Interest income	887	700
Other expense, net	(399)	(246)
Net loss before income tax benefit	(11,118)	(12,502)
Income tax (expense) benefit	(31)	248
Net loss	(11,149)	(12,254)
Other comprehensive loss:
Foreign currency translation adjustments	(1,229)	92
Unrealized gain on available-for-sale securities	7	235
Total comprehensive loss	$ (12,371)	$ (11,927)
Net loss per share - basic	$ (0.26)	$ (0.34)
Net loss per share - diluted	$ (0.26)	$ (0.34)
Weighted average shares of common stock outstanding - basic	43,010,212	35,855,200
Weighted average shares of common stock outstanding - diluted	43,010,212	35,855,200